Discounted Cash Flow
Ligand Pharmaceuticals Inc.
—
—
Average annual growth rates
| Metric | 10-Year | 5-Year | 3-Year |
|---|---|---|---|
| Sales | — | — | — |
| Free Cash Flow | — | — | — |
| Average (FCF & NI) | — | — | — |
| Net Income | — | — | — |
Endpoint CAGR (better for long term trend)
| Metric | 10-Year | 5-Year | 3-Year |
|---|---|---|---|
| Sales | — | — | — |
| Free Cash Flow | — | — | — |
| Average (FCF & NI) | — | — | — |
| Net Income | — | — | — |
Projected growth rate
—
—
%
%
Historical inputs (10 fiscal years)
| YEAR | Sales | Net Income | Free Cash Flow | Net Margin | EPS (diluted) |
|---|---|---|---|---|---|
| 2016 | $109.0m | $-1.6m | $-1.6m | -1.5% | $-0.08 |
| 2017 | $141.1m (29.5%) | $12.6m (867.5%) | $91.4m (5687.5%) | 8.9% (692.7%) | $0.60 (850.0%) |
| 2018 | $251.5m (78.2%) | $143.3m (1041.5%) | $193.2m (111.3%) | 57.0% (540.5%) | $6.77 (1028.3%) |
| 2019 | $120.3m (-52.2%) | $629.3m (339.1%) | $-31.9m (-116.5%) | 523.2% (817.9%) | $33.13 (389.4%) |
| 2020 | $186.4m (55.0%) | $-3.0m (-100.5%) | $-3.0m (90.6%) | -1.6% (-100.3%) | $-0.18 (-100.5%) |
| 2021 | $277.1m (48.7%) | $57.1m (2014.2%) | $70.0m (2446.3%) | 20.6% (1387.6%) | $3.44 (2011.1%) |
| 2022 | $196.2m (-29.2%) | $-33.4m (-158.4%) | $119.9m (71.2%) | -17.0% (-182.5%) | $-1.98 (-157.6%) |
| 2023 | $131.3m (-33.1%) | $52.2m (256.3%) | $46.1m (-61.6%) | 39.7% (333.6%) | $3.02 (252.5%) |
| 2024 | $167.1m (27.3%) | $-4.0m (-107.7%) | $-4.0m (-108.8%) | -2.4% (-106.1%) | $-0.22 (-107.3%) |
| 2025 | $268.1m (60.4%) | $124.5m (3186.6%) | $48.9m (1313.0%) | 46.4% (2024.3%) | $6.44 (3027.3%) |
Base FCF: — (latest fiscal year)
Discount rate: % —
Terminal growth: —
Projection period: — years
Alt A decline yrs:
Alt B total yrs:
Projected cash flows
| Year | Projected cash flow | Discount Factor | Present Value |
|---|
PV of projected FCF: —
Terminal FCF: —
Terminal value: —
PV of terminal value: —
Enterprise value (DCF): —
Current price: —
—Alternative DCF Models
| Model | Fair Value | Upside | PV(FCFs) | PV(Terminal) | Total Years |
|---|---|---|---|---|---|
| Standard (10yr→TV) | — | — | — | — | 10 + TV |
| Alt A (Gradual Decline) | — | — | — | — | — |
| Alt B (30yr Hard Stop) | — | — | — | N/A | — |
This is a simplified DCF model for illustration. It uses reported free cash flow, a single growth assumption, fixed WACC, and a Gordon Growth terminal value. It is not investment advice.